

CURRICULUM VITAE

03/27/22

PERSONAL INFORMATION

Uri Galili
910 S. Michigan Ave. Apt. 904
Chicago, IL 60605
Tel. 312-753-5997
Cell 312-722-4525
Email: uri.Galili@rcn.com

EDUCATION

1973 Hebrew University Medical School, Jerusalem, Israel
Major: Immunology
Degree Awarded: M.Sc.

1974 - 1977 Hebrew University Medical School, Jerusalem, Israel
Major: Immunology
Degree Awarded: Ph.D.

POSTDOCTORAL TRAINING

1977 - 1979 Karolinska Institute, Department of Tumor Biology, Stockholm, Sweden

ACADEMIC APPOINTMENTS

2014- To date Retired. Volunteering as adjunct professor at Division of Cardiology, Rush Medicine, performing research on myocardium regeneration post MI.

2008- 2013 Professor, Department of Surgery, University of Massachusetts Medical School, Worcester, MA 01655

2004- 2008 Professor, Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605

1999- 2004 Professor, Department of Cardiovascular-Thoracic Surgery, Department of Immunology and Microbiology, Rush University School of Medicine, Chicago IL.

1991 - 1999 Professor, Department of Microbiology and Immunology, MCP◆Hahnemann School of Medicine, Philadelphia, PA

1990 - 1991 Professor in Residence, Department of Laboratory Medicine and Department of Anatomy, University of California Medical Center, San Francisco, CA

1988 - 1990 Associate Professor (adjunct), Department of Laboratory Medicine and Department of Anatomy, University of California Medical Center, San Francisco, CA

1986 - 1988 Associate Research Immunologist, Cancer Research Institute, University of California Medical Center, San Francisco, CA

1984 - 1986 Visiting Scientist, Cancer Research Institute, University of California Medical Center, San Francisco, CA

1980 - 1984 Assistant Research Immunologist, Department of Hematology, Hadassah University Hospital, Jerusalem, Israel

HONORS AND AWARDS

2015	Honorary member International Xenotransplantation Association
1983 - 1986	Leukemia Society of America "Special Fellow"
1981 - 1983	Israel Cancer Research Fund Award
1980	Lady Davis Foundation Award
1977	International Union Against Cancer Award
2015	Honorary Member International Xenotransplantation Association

MEMBERSHIPS AND OFFICE IN PROFESSIONAL SOCIETIES

American Association of Immunology
American Society of Biochemistry & Molecular Biology
American Society of Hematology
American Society for Complex Carbohydrates
Society of Clinical Immunology
American Aging Association
Xenotransplantation Society

BIBLIOGRAPHY

Peer Reviewed Papers

1. Schlesinger, M. and U. Galili. Antigenic differences between T and B lymphocytes in man. *Israel J. Med. Sci.* **10**:715-721, 1974.
2. Galili, U. and M. Schlesinger. The formation of stable E-rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells. *J. Immunol.* **112**:1628-1934, 1974.
3. Galili, U. and M. Schlesinger. Subpopulations of human thymus cells differing in their capacity to form stable E-rosettes and their immunologic reactivity. *J. Immunol.* **115**:827-833, 1975.
4. Galili, U., M. Eliakim, S. Slavin and M. Schlesinger. Lymphocyte subpopulations in chronic active hepatitis: Increase in lymphocytes forming stable E-rosettes. *Clin. Immunol. Immunopathol.* **4**:538-544, 1975.
5. Galili, U. and M. Schlesinger. Studies on the formation of E-rosettes by human T-lymphocytes and thymus cells. *Israel J. Med. Sci.* **11**:1357-1367, 1975.
6. Raben, M., N. Wallach, U. Galili, and M. Schlesinger. The effects of radiation therapy on lymphocyte subpopulations in cancer patients. *Cancer* **37**:1417, 1976.
7. Galili, U. and M. Schlesinger. The formation of stable E-rosettes by human T-lymphocytes activated in mixed lymphocyte reaction. *J. Immunol.* **117**:730-735, 1976.
8. Ben-Zvi, A., U. Galili, A. Russell and M. Schlesinger. Age associated changes in subpopulations of human lymphocytes. *Clin. Immunol. Immunopathol.* **7**:139-147, 1977.
9. Galili, U., E. Klein and M. Schlesinger. Human T-lymphocyte receptors for sheep red blood cells and specific T antigens: Are they identical sites on the cell membrane? *J. Immunol.* **119**:104-109, 1977.

10. **Galili, U.**, M. Caine, C. Servadio, and M. Schlesinger. Attachment of T-lymphocytes from bladder carcinoma patients to monolayers of cancer cells: An assay for tumor recognition by peripheral blood lymphocytes. *Cancer Lett.* **3**:121-124, 1977.
11. **Galili, U.**, C. Brautbar, and M. Schlesinger. Association between HLA determinants and complement receptors on human lymphocytes. *Tissue Antigens* **10**:99-107, 1977.
12. **Galili, U.** and M. Schlesinger. Regulation of the cytotoxic effect of human 'Normal killer cells' on tumor cell lines by neuraminidase treated T-lymphocytes. *Cancer Immunol. Immunother* **4**:33-39, 1978.
13. **Galili, U.**, N. Galili, F. Vanky and E. Klein. Natural species-restricted attachment of human and murine T-lymphocytes to various cells. *Proc. Natl. Acad. Sci. USA* **75**:2396-2400, 1978.
14. **Galili, U.**, L. Rosenthal, N. Galili, and E. Klein. Activated T cells in the synovial fluid of arthritic patients: Characterization and comparison with in vitro activated human and murine T cell in cooperation with monocytes in cytotoxicity. *J. Immunol.* **122**:878-883, 1979.
15. **Galili, U.**, F. Vanky, L. Rodriguez, and E. Klein. Activated T lymphocytes within human solid tumors. *Cancer Immunol. Immunother.* **6**:129-133, 1979.
16. **Galili, U.**, P. Hayry and E. Klein. Loss of net negative surface charge during MLC stimulation of human T lymphocytes. Correlation to stable E-rosette formation and natural attachment to normal and malignant cells. *Cell Immunol.* **48**:91-99, 1979.
17. **Galili, U.**, E. Klein, B. Christensson and P. Biberfeld. Lymphocytes in Hodgkin's biopsies exhibit: Stable E rosette formation, natural attachment and glucocorticoid sensitivity, similar to immunoactivated T cells. *Clin. Immunol. Immunopathol* **16**:173-179, 1980.
18. Galili, N., **U. Galili**, E. Klein, L. Rosenthal and B Nordenskjold. Human T lymphocytes become glucocorticoid sensitive upon immune activation. *Cell Immunol* **50**:440-444, 1980.
19. **Galili, U.**, E. Klein, G. Klein, and I.S. Bal. Activated T lymphocytes in infiltrates and draining lymph nodes of nasopharyngeal carcinoma. *Int. J. Cancer* **25**:85-89, 1980.
20. **Galili, U.**, J. Seely, E. Svedmyr, E. Klein, G. Klein and O. Weiland. Blood lymphocytes in infectious mononucleosis share the following characteristics with activated T cells: Natural attachment, stable E rosetting and glucocorticoid sensitivity. *J. Clin. Lab. Immunol.* **3**:153-158, 1980.
21. **Galili, U.**, E. Klein, G. Klein, and P. Biberfeld. The natural attachment of thymocytes and activated T lymphocytes to normal and malignant cells: An interspecies study. *Dev Comp. Immunol.* **4**:367-374, 1980.
22. **Galili, U.**, M. Prokocimer and G. Izak. The in vitro sensitivity of leukemic and normal leukocytes to hydrocortisone induced cytolysis. *Blood* **56**:1077-1081, 1980.
23. **Galili, U.**, N. Manny, and G. Izak. EA rosette formation: A simple means to increase sensitivity of antiglobulin test in patients with anti red cell antibodies. *Br. J. Haematol.* **47**:227-233, 1980.
24. **Galili, U.**, A. Polliack, E. Okon, R. Leizerovitz, H. Gamliel, A. Korkesh, J.C. Schenker and G. Izak. Human prothymocytes: Membrane properties, differentiation patterns, glucocorticoid sensitivity and ultrastructural features. *J. Exp. Med.* **152**:796-807, 1980.

25. **Galili, U.**, N. Galili, R. Or and A. Polliack. Analysis of the peanut agglutinin-binding site as a differentiation marker of normal and malignant human lymphoid cells. *Clin. Exp. Immunol.* **43**:311-318, 1981.
26. Cividalli, G., S. Yatziv, R. Voss, **U. Galili**, J. Kopolovic, M. Sagi, Z. Weizman, C. Brautbar, G. Cohen. XX/YY lymphoid chimerism in a boy with fatal lymphohistiocytic proliferation. *JAMA* **246**:1917-1920, 1981.
27. Galili, N., **U. Galili**, A. Ravid, M. Schlesinger, and N. Goldblum. Induction of differentiation with phorbol ester in a human T cell line Be13 expressing both prothymocyte and thymocyte characteristics. *Hum. Lymphocyte Differentiation* **1**:123-130, 1981.
28. **Galili, U.**, L. Rosenthal and E. Klein. Activated T cells in the synovial fluid of arthritic patients. II. In vitro activation of the autologous blood lymphocytes. *J. Immunol.* **127**:430-432, 1981.
29. **Galili, U.**, R. Leizerowitz, J. Moreb, H. Gamliel, D. Gurfel and A. Polliack. The in vitro lysis of chronic lymphocytic leukemia cells by glucocorticoids: Metabolic and ultrastructural aspects of the killing process. *Cancer Res.* **42**:1433-1440, 1982.
30. Mayer, M., **U. Galili**, and M. Kaiser. Intracellular protease activity in glucocorticoid mediated cytolysis. *Endocrinology* **110**:2131-2137, 1982.
31. **Galili, U.**, A. Korkesh, I. Kahane and E.A. Rachmilewitz. Demonstration of a natural anti-galactosyl IgG antibody on thalassemic red blood cells. *Blood* **61**:1258-1264, 1983.
32. Cano Castellanos, R., R. Leizerowitz, N. Kaiser, A. Polliack, A Korkesh and **U. Galili**. Prothymocytes in postirradiation regenerating rat thymuses: A model for studying early stages in T cell differentiation. *J. Immunol.* **130**:121-130, 1983.
33. Polliack, A., R. Leizerowitz, A. Korkesh, D. Gurfel, H. Gamliel and **U. Galili**. Exposure to phorbol diester (TPA) in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias: In vitro differentiation, growth patterns, and ultrastructural observations. *Am. J. Hematol.* **13**:199-211, 1982.
34. Granat, M., J.G. Schenker, S. Mor-Yosef, E. Rosenkovitch, R. Cano Castellanos and **U. Galili**. Effect of dexamethasone on proliferation of autologous fibroblasts and on immune profile in women undergoing pelvic surgery for infertility. *Fertil. Steril.* **39**:180-186, 1983.
35. **Galili, U.** Glucocorticoid-induced cytolysis of human normal and malignant lymphocytes. *J. Steroid Biochem.* **19**:483-490, 1983.
36. Sharon, R. and **U. Galili**. The rosetting antiglobulin test as a means of determining the D zygosity of human red cells. *Vox Sang* **46**:175-179, 1984.
37. **Galili, U.**, A. Peleg, Y. Milner and N. Galili. Be13, a human T leukemia cell line highly sensitive to dexamethasone-induced cytolysis. *Cancer Res.* **44**:4594-4601, 1984.
38. **Galili, U.**, E.A. Rachmilewitz, A. Peleg, and I. Flechner. A unique natural human IgG antibody with anti- α -galactosyl specificity. *J. Exp. Med.* **160**:1519-1531, 1984.

39. **Galili, U.**, B.A. Macher, J. Buehler and S.B. Shohet. Human natural anti- α -galactosyl IgG. II. The specific recognition of $\alpha(1\rightarrow3)$ -linked galactose residues. *J. Exp. Med.* **162**:573-582, 1985.
40. **Galili, U.**, I. Flechner, A. Kniszinski, D. Danon and E.A. Rachmilewitz. The natural anti- α -galactosyl IgG on human normal senescent red blood cells. *Br. J. Haematol.* **62**:317-324, 1986.
41. **Galili, U.**, M.R. Clark and S.B. Shohet. Excessive binding of the natural anti- α -galactosyl IgG to sickle red cells may contribute to extravascular cell destruction. *J. Clin. Invest.* **77**:27-33, 1986.
42. Sharon, R., J.S. Duke-Cohan and **U. Galili**. Determination of ABO blood group zygosity by an antiglobulin rosetting technique and cell-based enzyme immunoassay. *Vox Sang.* **50**:245-249, 1986.
43. **Galili, U.**, M.R. Clark, S.B. Shohet, J. Buehler and B.A. Macher. Evolutionary relationship between the anti-Gal antibody and the Gal $\alpha 1\rightarrow 3$ Gal epitope in primates. *Proc. Natl. Acad. Sci (USA)* **84**:1369-1373, 1987.
44. **Galili, U.**, J. Buehler, S.B. Shohet and B.A. Macher. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. *J. Exp. Med.* **165**:693-704, 1987.
45. **Galili, U.**, C. Basbaum, S.B. Shohet, J. Buehler and B.A. Macher. Identification of erythrocyte Gal $\alpha 1\rightarrow 3$ Gal glycosphingolipids with a mouse monoclonal antibody Gal-13. *J. Biol. Chem.* **262**:4683-4688, 1987.
46. Buehler, J., **U. Galili**, and B.A. Macher. Use of enzyme-linked immunoadsorbent assay to monitor the purification of glycosphingolipid antigens by high-performance liquid chromatography. *Anal. Biochem.* **164**:521-525, 1987.
47. Lane, P.A., **U. Galili**, T.A. Iarocci, R.A. Shaw and W.C. Mentzer. Cellular dehydration and immunoglobulin binding in senescent neonatal erythrocytes. *Pediatr. Res.* **23**:288-292, 1988.
48. **Galili, U.**, R.E. Mandrell, R.M. Hamahdeh, S.B. Shohet and J.M. Griffis. Interaction between human natural anti- α -galactosyl immunoglobulin G and bacteria of the human flora. *Infect. Immun.* **56**:1730-1737, 1988.
49. **Galili, U.**, S.B. Shohet, E. Kobrin, C.L.M. Stults and B.A. Macher. Man, apes, and Old World monkeys differ from other mammals in the expression of α -galactosyl epitopes on nucleated cells. *J. Biol. Chem.* **263**:17755-17762, 1988.
50. Avila, J.L., M. Rojas and **U. Galili**. Immunogenic Gal $\alpha 1\rightarrow 3$ Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. *J. Immunol.* **142**:2828-2834, 1989.
51. **Galili, U.** Abnormal expression of α -galactosyl epitopes in man: A trigger for autoimmune processes? *Lancet* **ii**:358-361, 1989.
52. Thall, A. and **U. Galili**. The differential expression of Gal $\alpha 1\rightarrow 3$ Gal $\beta 1\rightarrow 4$ GlcNAc-R residues on mammalian secreted N-glycosylated glycoproteins. *Biochemistry* **29**:3959-3965, 1990.

53. Sorette, M.P., U. Galili and M.R. Clark. Comparison of serum anti-band 3 and anti-Gal antibody binding to density separated human red blood cells. *Blood* **77**:628-636, 1991.
54. Thall, A., J. Etienne-Decerf, R. Winand and U. Galili. The α -Galactosyl epitopes on human normal and autoimmune diseased thyroid cells. *Autoimmunity* **10**:81-88, 1991.
55. Thall, A., J. Etienne-Decerf, R. Winand and U. Galili. The α -galactosyl epitope on mammalian thyroid cells. *Acta Endocrin.* **124**:692-699, 1991.
56. Galili, U. and K. Swanson. Gene sequences suggest inactivation of α 1-3 galactosyltransferase in catarrhines after the divergence of apes from monkeys. *Proc. Natl. Acad. Sci. USA* **88**:7401-7404, 1991.
57. Hamadeh, R.M., G.A. Jarvis, U. Galili, R.E. Mandrell, P. Zhou and J.M. Griffiss. Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. *J. Clin. Invest.* **89**:1223-1235, 1992.
58. Galili, U., M. Ron and R. Sharon. The natural anti- α -galactosyl IgG in seminal fluid. A simple means to determine damage to the blood genital tract barrier in infertile males. *J. Immunol. Methods* **151**:117-122, 1992.
59. Heda, G.H., T.R. Henion and U. Galili. A simple *in vitro* site directed mutagenesis of concatamerized cDNA by inverse polymerase chain reaction. *Nucl. Acid Res.* **20**:5241-5242, 1992.
60. Galili, U. Interaction of the natural anti-Gal antibody with α -galactosyl epitopes: A major obstacle for xenotransplantation in humans. *Immunology Today* **14**:480-482, 1993.
61. Winand, R.J., F. Anaraki, J. Etienne-Decerf and U. Galili. Xenogeneic TSH like activity of the human natural anti-Gal antibody: Interaction of anti-Gal with porcine thyrocytes and with recombinant human TSH receptors expressed on mouse cells. *J. Immunol.* **151**:3923-3934, 1993.
62. Gorelik, E., M. Kim, L. Duty, T. Henion and U. Galili. Control of metastatic properties of BL6 melanoma cells by H-2K^b gene: Immunological and nonimmunological mechanisms. *Clin. Exp. Metastases* **11**:439-452, 1993.
63. Kim, M., M.V. Rao, D.J. Tweardy, M. Prakash, U. Galili and E. Gorelik. Lectin-induced apoptosis of tumor cells. *Glycobiology* **3**:447-453, 1993.
64. Galili, U., F. Anaraki, A. Thall, C. Hill-Black and M. Radic. One percent of circulating B lymphocytes are capable of producing the natural anti-Gal antibody. *Blood* **82**:2485-2493, 1993.
65. Henion, T.R., B.A. Macher, F. Anaraki and U. Galili. Defining the minimal size of catalytically active primate α 1,3 galactosyltransferase: Structure function studies on the recombinant truncated enzyme. *Glycobiology* **4**:193-201, 1994.
66. Repik, P.M., J.M. Strizki and U. Galili. Differential host dependent expression of α -galactosyl epitopes on viral glycoproteins: A study of Eastern equine encephalitis virus as a model. *J. Gen. Virol.* **75**:1177-1181, 1994.

67. Winand, R.J., J. Winand-Devigne, M. Meurisse and U. Galili. Specific stimulation of Graves' disease thyrocytes by the natural anti-Gal antibody from normal and autologous serum. *J. Immunol.* **153**:1386-1395, 1994.
68. Hamadeh, R.M., U. Galili, P. Zhou and J.M. Griffis. Human secretions contain IgA, IgG and IgM anti-Gal (anti- α -galactosyl) antibodies. *Clin. Diagnos. Lab. Immunol.* **2**:125-131, 1995.
69. Wang, L., F. Anaraki, T.R. Henion and U. Galili. Variations in activity of the human natural anti-Gal antibody in young and elderly populations. *J. Gerontol. (Med. Sci.)*, **50A**:M227-M233, 1995.
70. Galili, U., A. Tibell, B. Samuelsson, L. Rydberg and C.G. Groth. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. *Transplantation* **59**:1549-1556, 1995.
71. Galili, U., C.R. Gregory and R.E. Morris. Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. *Transplantation* **60**:210-213, 1995.
72. Galili, U. and P. Andrews. Suppression of α -galactosyl epitopes synthesis and production of the natural anti-Gal antibody: A major evolutionary event in ancestral Old World primates. *J. Human Evolution* **29**:433-442, 1995.
73. Wang, L., M.Z. Radic and U. Galili. Human anti-Gal heavy chain genes: Preferential use of V_H3 and the presence of somatic mutations. *J. Immunol.* **155**:1276-1285, 1995.
74. Gorelik, E., L. Duty, F. Anaraki and U. Galili. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α 1,3galactosyltransferase gene transfection. *Cancer Res.* **55**:4168-4173, 1995.
75. Galili, U. and F. Anaraki. Synthesis of the α -galactosyl (Gal α 1-3Gal β 1-4GlcNAc-R) epitope on humans cells by recombinant primate α 1,3galactosyltransferase expressed in *E. coli*. *Glycobiology* **5**:775-782, 1995.
76. Pothoulakis, C., U. Galili, I. Castagliuolo, S. Kelly, P.K. Nikulasson, T.A. Brasitus and J.T. Lamont. Human anti-Gal IgG binds to the same receptors and mimics the effects of *C. difficile* Toxin A in rat colon. *Gastroenterology* **98**:641-649, 1996.
77. Galili, U., P.K. Repik, F. Anaraki, K. Mozdzanowska, G. Washko and W. Gerhard Enhancement of antigen presentation of influenza virus hemagglutinin by the natural anti-Gal antibody. *Vaccine* **14**:321-328, 1996.
78. Galili, U. and K.L. Matta. Inhibition of anti-Gal IgG binding to porcine endothelial cells by synthetic oligosaccharides. *Transplantation* **62**:356-262, 1996.
79. LaTemple, D.C., T.R. Henion, F. Anaraki and U. Galili. Synthesis of α -galactosyl epitopes by recombinant α 1,3galactosyltransferase for opsonization of human tumor cell vaccines by anti-Gal. *Cancer Res.* **56**:3069-3074, 1996.
80. Tenebergs, S., I. Lönnroth, J.F. Torres Lopez, U. Galili, M. Olwegard Halvarsson, J. Angstrom and K-A. Karlsson. Mowanglecular mimicry in the recognition of glycosphingolipids by Gal α 3Gal β 4GlcNAc β -binding *Clostridium difficile* toxin A, human natural anti- α -galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor. *Glycobiology* **6**:599-609, 1996.

81. Stone, K.R., A.W. Walgenbach, T. Abrams, J. Nelson, N. Gellett and U. Galili. Porcine and bovine cartilage transplants in cynomolgus monkey: I. A model for chronic xenograft rejection. *Transplantation*, **63**:640-645, 1997.
82. Galili, U., D.C. LaTemple, A.W. Walgenbach and K.R. Stone. Porcine and bovine cartilage transplants in cynomolgus monkey: II. Changes in anti-Gal response during chronic rejection. *Transplantation*, **63**:646-651, 1997.
83. Gorelik, E., F. Xu, T. Henion, F. Anaraki and U. Galili. Reduction in metastatic properties of BL6 melanoma cells expressing terminal Fuc α 1-2Gal after α 1,2fucosyltransferase cDNA transfection. *Cancer Research*, **57**:332-336, 1997.
84. Galili, U. and D.C. LaTemple. The natural anti-Gal antibody as a universal augmentor of autologous tumor vaccine immunogenicity. *Immunology Today*, **18**:281-285, 1997.
85. Henion, T.R., W. Gerhard, F. Anaraki and U. Galili. Synthesis of α -gal epitopes on influenza virus vaccines by recombinant α 1,3galactosyltransferase enables the formation of immune complexes with the natural anti-Gal antibody. *Vaccine*, **15**:1174-1182, 1997.
86. Wang, L., M.Z. Radic, D. Siegel, T. Chang, J. Bracey and U. Galili. Cloning of anti-Gal Fabs from combinatorial phage display libraries: Structural analysis and comparison of Fab expression in pComb3^H and pComb8 phage. *Molecular Immunology*, **34**:609-618, 1997.
87. Galili, U., D.C. LaTemple and M.Z. Radic. A sensitive assay for measuring α -gal epitope expression on cells by a monoclonal anti-Gal antibody. *Transplantation*, **65**:1129-1132, 1998.
88. Shinkel, T.A., C.G. Chen, E. Salvaris, T.R. Henion, H. Barlow, U. Galili, M.J. Pearse and A.J. d'Apice. Changes in cell surface glycosylation in α -galactosyltransferase knock-out and α 1,2fucosyltransferase transgenic mice. *Transplantation*, **64**:197-204, 1997.
89. Palmetshofer, A., U. Galili, A.P. Dalmaso, S.C. Robson and F.H. Bach. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type I activation. *Transplantation*, **65**:844-853, 1998.
90. Palmetshofer, A., U. Galili, A.P. Dalmaso, S.C. Robson and F.H. Bach. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type II activation. *Transplantation*, **65**:971-978, 1998.
91. Minanov, O.P., J.H. Artrip, M. Szabolcs, P.A. Kwiatkowski, U. Galili, S. Itescu and R.E. Michler. Triple immunosuppression reduces mononuclear cell infiltration and prolongs graft life in pig-to-newborn baboon cardiac xenotransplantation. *J. Thorac. Cardiovasc. Surg.*, **115**:998-1006, 1998.
92. LaTemple, D.C. and U. Galili. Adult and neonatal anti-Gal response in knock-out mice for α -1,3galactosyltransferase. *Xenotransplantation*, **5**:191-196, 1998.
93. Stone, K.R., G. Ayala, J. Goldstein, R. Hurst, A. Walgenbach and U. Galili. Porcine cartilage transplants in cynomolgus monkey: III. Transplantation of α -galactosidase treated porcine cartilage. *Transplantation*, **65**:1577-1583, 1998.

94. LaTemple, D.C., J.T. Abrams, S.U. Zhang and **U. Galili**. Increased immunogenicity of tumor vaccines complexed with anti-Gal: Studies in knock out mice for α 1,3galactosyltransferase. *Cancer Research*, **59**: 3417-3423, 1999.
95. Maruyama S, Cantu E 3rd, **Galili U**, D'Agati V, Godman G, Stern DM, Andres G. α -galactosyl epitopes on glycoproteins of porcine renal extracellular matrix. *Kidney Int.* **57**: 655-63, 2000.
96. Maruyama S, Cantu E3rd, Pernis B, **Galili U**, Godman G, Stern DM, Andres G. Alpha-galactosyl antibody redistributes α -galactosyl at the surface of pig blood and endothelial cells. *Transpl Immunol* **7**:101-6, 2000.
97. Maruyama S, Cantu E 3rd, DeMartino C, Wang CY, Chen J, Al-Mohanna F, Nakeeb SM, D'Agati V, Pernis B, **Galili U**, Godman G, Stern DM, Andres G. Interaction of baboon anti- α -galactosyl antibody with pig tissues. *Am J Pathol.* **155**:1635-49, 1999.
98. Tanemura, M., S. Maruyama and **U. Galili**. Differential expression of α -gal epitopes (Gal α 1-3Gal β 1-4GlcNAc-R) on pig and mouse organs. *Transplantation*, **69**:187-190, 2000.
99. Tanemura, M., Yin, D., Chong, A. S., and **U. Galili**. Differential immune response to α -gal epitopes on xenografts and allografts: Implications for accommodation in xenotransplantation. *J. Clinical Investigation* **105**: 301-310, 2000.
100. Tanemura M, **Galili U**. T cells interacting with the α -Gal epitope: studies in α 1, 3Galactosyltransferase knock-out mice. *Transplant Proc* **32**:921-923, 2000.
101. Tanemura M, **Galili U**. Identification of B cells with receptors for α -Gal epitopes (Gal α 1-3Gal β 1-4GlcNAc-R) in xenograft recipients. *Transplant Proc* **32**:857-858,2000.
102. Chen Z.C., M.Z.Radic and **U. Galili**. Genes coding evolutionary novel anti-carbohydrate antibodies: Studies on anti-Gal induction in α 1,3galactosyltransferase knock out mice. *Molecular Immunol.* **37**: 455-466, 2000.
103. Tanemura, M., D. Yin, D.J. DiSesa, and **U. Galili**. Preventing anti-Gal response in xenograft recipients by an α -gal toxin. *Transplant. Proc.* **33**: 699-700, 2001.
104. Chen, Z.C., M. Tanemura and **U. Galili**. Synthesis of α -gal epitopes (Gal α 1-3Gal β 1-4GlcNAc-R) on human tumor cells by recombinant α 1,3galactosyltransferase produced in *Pichia pastoris*. *Glycobiology* **11**: 11:577-586, 2001.
105. Gorelik E, **U. Galili** and A. Raz. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. *Cancer Metastasis Rev.* **20**:245-77, 2001.
106. Deriy, L., Z. Chen, G. Gao and **U. Galili**. Expression of α -Gal epitopes (Gal α 1-3Gal β 1-4GlcNAc-R) on human cells following transduction with adenovirus vector containing α 1,3galactosyltransferase cDNA. *Glycobiology*, **12**:135-144, 2002.
107. Tanemura, M., H. Ogawa, D.P., Yin, Z.C.Chen, V.J. DiSesa and **U. Galili**. Specific elimination of anti-Gal B cells in xenograft recipients by α -gal ricin. *Transplantation* **73**: 1859-1868, 2002.
108. Tanemura, M., A.S. Chong, V.J.DiSesa and **U. Galili**. Direct killing of xenograft cells by CD8+ T cells of discordant xenograft recipients. *Transplantation*, **74**: 1587-1595, 2002.

109. **Galili, U.**, H. Ishida, K. Toma, and H. Tanabe. Anti-Gal A/B, a novel anti-blood group antibody identified in recipients of ABO incompatible kidney allografts. *Transplantation* **74**: 1574-1580, 2002.
110. Mohiuddin, M. M., H. Ogawa, D. Yin, J. Shen and **U. Galili**. Antibody mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. *Transplantation* **75**: 258-262, 2003.
111. Ogawa, H., D-Y. Yin, J. Shen and **U. Galili**. Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen. *Blood* **101**:2318-2320, 2003.
112. Mohiuddin M, H. Ogawa, D. Yin and **U. Galili**. Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen.: II. Tolerance induction on memory B cells. *Blood*, **102**: 229-236, 2003.
113. **Galili U**, Z. Chen and K. DeGeest. Expression of α -gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. *Gynecologic Oncology* **90**: 100-108, 2003.
114. Leventhal JR, Sun J, Zhang J, **Galili U**, Chong A, Baker M, Kaufman DB, Wright JR Jr. Evidence that tilapia islets do not express α -(1,3)gal: implications for islet xenotransplantation. *Xenotransplantation*. **11**: 276-283, 2004.
115. Ogawa O., M.M. Mohiuddin, D. Yin, J. Shen, A.S. Chong and **U. Galili**. Mouse heart grafts expressing an incompatible carbohydrate antigen: II. Transition from accommodation to tolerance. *Transplantation* **77**: 366-373, 2004.
116. Ogawa O., D. Yin, and **U. Galili**. Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene. *Gene Therapy*, **11**: 292-301, 2004.
117. Kirchhof N, Shibata S, Wijkstrom M, Kulick DM, Salerno CT, Clemmings SM, Heremans Y, **Galili U**, Sutherland DE, Dalmaso AP, Hering BJ. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. *Xenotransplantation*. **11**: 396-407, 2004.
118. **Galili, U**. Autologous tumor vaccines processed to express α -gal epitopes: A practical approach to immunotherapy in cancer. *Cancer Immunology Immunotherapy* **53**: 935-945, 2004.
119. **Galili, U**. Immune response, accommodation and tolerance to transplantation carbohydrate antigens. *Transplantation* **78**: 1093-1098, 2004.
120. Manches, O., Plumas, J., Lui, L., Chaperot, L., Molens, J.P., Sotto, J.J., Bensa, J.C., and **Galili U**. Anti-Gal mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy with autologous tumor cells. *Haematologica* **90**: 625-634, 2005.
121. Deriy, L., H. Ogawa, G. Gao and **U, Galili**. In vivo targeting of vaccinating tumor cells to antigen presenting cells by a gene therapy method with adenovirus containing the α 1,3galactosyltransferase gene. *Cancer Gene Therapy* **12**: 528-539, 2005.

122. Ogawa, H. and U, **Galili**. Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay. *Glycoconjugate J.* **23**: 663-674, 2006.
123. Abdel-Motal, U., S.Wang, S. Lu, K. Wigglesworth and U. **Galili**. Increased immunogenicity of HIV gp120 engineered to express α -gal epitopes. *J. Virol.* **80**: 6943-6951, 2006.
124. Stone, K.R., A.W. Walgenbach, T.J. Turek, D.L. Somers, W. Wicomb and U. **Galili**. Anterior cruciate ligament reconstruction with a porcine xenograft: a serologic, histologic, and biomechanical study in primates. *Arthroscopy.* **23**:411-9, 2007.
125. Stone K.R., U. Abdel-Motal, A.W. Walgenbach, T. J. Turek and U. **Galili**. Replacement of human anterior cruciate ligament with pig ligament: a model for anti-non gal antibody response in long-term xenotransplantation. *Transplantation,* **83**: 211-219, 2007.
126. Abdel-Motal U.M., H.M. Guay, K. Wigglesworth, R.M. Welsh and U. **Galili** . Increased immunogenicity of influenza virus vaccine by anti-Gal mediated targeting to antigen presenting cells. *J. Virol.* **81**: 9131-9141. 2007.
127. **Galili, U.**, K. Wigglesworth and U. M. Abdel-Motal. Intratumoral injection of α -gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. *J. Immunol.* **178**: 4676-4687, 2007.
128. Abdel-Motal U.M., K. Wigglesworth, and U. **Galili** . Intratumoral injection of α -gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. *Cancer Immunology Immunotherapy,* **58**: 1545-56, 2009.
129. Abdel-Motal U.M., K. Wigglesworth, and U. **Galili** . Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. *VACCINE* **27**: 3072-3082, 2009.
130. **Galili, U.**, K. Wigglesworth and U. M. Abdel-Motal. Accelerated healing of skin burns by anti-Gal/ α -gal liposomes interaction. *BURNS* **36**: 239-251, 2010.
131. Abdel-Motal, U.M., S, Wang, A. Awwad, S. Lu, K. Wigglesworth, and U. **Galili**. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing α -gal epitopes. *VACCINE* **28**:1758-1765, 2010.
132. Wigglesworth, K, W.J.Racki, R. Mishra, E. Szomolany-Tsuda, D.L.Greiner and U. **Galili**. Rapid recruitment and activation of macrophages by anti-Gal/ α -gal liposome interaction accelerates wound healing. *J. Immunol.* **186**: 4422-4432, 2011.
133. **Galili, U.** Induced anti-non gal antibodies in human xenograft recipients. *Transplantation,* **93**: 11-16, 2012.
134. Hurwitz, Z., R. Ignatz, J. Lalikos and U. **Galili**. Accelerated porcine wound healing with α -Gal nanoparticles. *Plastic and Reconstructive Surgery,* **129**: 242-251, 2012.
135. Whalen GF, M. Sullivan, B. Piperdi, W. Wasseff, U. **Galili**. Cancer Immunotherapy by intratumoral injection of α -gal glycolipids. *Anticancer Research* **32**: 3861-68, 2012.

136. **Galili, U.** Anti-Gal: An abundant human natural antibody of multiple pathogeneses and clinical benefits. *Immunology* **140**:1-11, 2013.
137. **Galili, U.** α 1,3Galactosyltransferase knockout pigs produce the natural anti-Gal antibody and simulate the evolutionary appearance of this antibody in primates. *Xenotransplantation* **20**: 267–276, 2013.
138. **Galili, U.** Anti-Gal macrophage recruitment and activation by α -gal nanoparticles accelerate regeneration and can improve biomaterials efficacy in tissue engineering. *The Open Tissue Engineering and Regenerative Medicine Journal*, **6**: 1-11, 2013.
139. **Galili, U.** Avoiding Detrimental Human Immune Response Against Mammalian Extracellular Matrix Implants. *Tissue Engineering, Part B*, **21**: 231-241, 2015.
140. **Galili, U.** Acceleration of wound healing by α -gal nanoparticles interacting with the natural anti-Gal antibody. *J. Immunol. Res.* **Vol. 2015**, Article ID 589648 April 2015.
141. Kristian, S.A., J. H. Hwang, B. Hall, E. Leire., J. Iacomini, R. Old, **U. Galili**, C. Roberts, K. B. Mullis, M. Westby and V. Nizet. Retargeting Preexisting Human Antibodies to a Bacterial Pathogen with an α -Gal Conjugated Aptamer. *Journal of Molecular Medicine*, **93**: 619-31, 2015.
142. **Galili, U.** Significance of the evolutionary α 1,3galactosyltransferase (*GGT1*) gene inactivation in preventing extinction of apes and Old World monkeys. *Journal of Molecular Evolution*. **80**: 1-9, 2015.
143. Albertini MR, Ranheim EA, Zuleger CL, Sondel PM, Hank JA, Bridges A, Newton MA, McFarland T, Collins J, Clements E, Henry MB, Neuman HB, Weber S, Whalen G, **Galili U.** Phase I study to evaluate toxicity and feasibility of intratumoral injection of α -gal glycolipids in patients with advanced melanoma. *Cancer Immunol Immunother.* **65**: 897-907, 2016.
144. **Galili U.** Natural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics?. *Glycobiology*, **26**: 1140-1150, 2016.
145. **Galili U.** α -Gal Nanoparticles in Wound and Burn Healing Acceleration. *Advances in Wound Care.* **6**: 81-91, 2017.
146. Stone, K.R., A. Walgenbach and **U. Galili.** Induced remodeling of porcine tendons to human anterior cruciate ligaments by α -gal epitope removal and partial crosslinking. *Tissue Engineering B*, **23**: 412-419, 2017.
147. Kaymakcalan OE, Karinja S, Abadeer A, Dong X, Jin JL, **Galili U**, Spector JA. Antigen-Mediated, Macrophage-Stimulated, Accelerated Wound Healing Using α -Gal Nanoparticles. *Ann Plast Surg.* **80**(4 Suppl 4):S196-S203. 2018.
148. **Galili U.** Evolution in primates by “Catastrophic-selection” interplay between enveloped virus epidemics, mutated genes of enzymes synthesizing carbohydrate antigens and natural anti-carbohydrate antibodies. *American Journal of Physical Anthropology*, **168**: 352-363, 2019.
149. Kaymakcalan OE, Abadeer A, Goldufsky JW, **Galili U**, Karinja SJ, Dong X, Jin JL, Samadi A, Spector JA, Topical α -Gal Nanoparticles Accelerate Diabetic Wound Healing. *Experimental Dermatology* **29**: 404-413, 2020.

150. **Galili U.** Human Natural Antibodies to Mammalian Carbohydrate Antigens as Unsung Heroes Protecting Against Past, Present, and Future Viral Infections. *Antibodies*, 9 (2): E25, 2020.
151. **Galili U.** Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α -gal epitopes. *Vaccine* 38: 6487-6499, 2020,
152. **Galili U.** Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as “Achilles’ Heel” of Viruses Contributing to Anti-Viral Immune Protection. *International Journal of Molecular Sciences* 21: 6702; 2020.
153. **Galili U, Stone KR.** In Situ "Humanization" of Porcine Bioprostheses: Demonstration of Tendon Bioprostheses Conversion into Human ACL and Possible Implications for Heart Valve Bioprostheses. *Bioengineering* (Basel). 8(1):E10. doi: 10.3390, 2021.
154. **Galili U,** Increasing efficacy of inactivated enveloped virus vaccines by in situ immune complexing with the natural anti-Gal antibody. *Medical Research Archives*, Jul;9(7):2481, 2021.
155. **Samadi A, Buro J, Dong X, Weinstein A, Lara DO, Celie KB, Wright MA, Gadjiko MA, Galili U, Spector JA.** Topical α -Gal Nanoparticles Enhance Wound Healing in Radiated Skin. *Skin Pharmacology and Physiology*, 35:31-40, 2021.
156. **Galili U,** Covid-19 variants as moving targets and how to stop them by glycoengineered whole-virus vaccines. *Virulence* 12: 1717-1720, 2021.
157. **Galili U, Zhu Z, Chen J, Goldufsky JW, Schaer GL.** Near complete repair after myocardial infarction in adult mice by altering the inflammatory response with intramyocardial injection of α -gal nanoparticles. *Frontiers in Cardiovascular Medicine*, August 25;8:719160, 2021.
158. **Galili U.** Biosynthesis of α -gal epitopes (Gal α 1-3Gal β 1-4GlcNAc-R) and their unique potential in future α -gal therapies. *Frontiers In Molecular Biosciences* Nov 4;8:746883, 2021.

Books Editing and Writing

1. **Galili, U.** and J.L. Avila. Editing the book “ α -Gal and Anti-Gal : α 1,3galactosyltransferase, α -gal epitopes and the natural anti-Gal antibody.” Published by KLUWER&PLENUM Press, ”Subcellular Biochemistry”, Vol. 32: 1999, and writing 6 of the 15 chapters in this book (see below).
2. **Galili, U.,** writing the book “The natural anti-Gal antibody as foe turned friend in medicine”, published by Elsevier/Academic Press, London, 2018.

Book Chapters

1. **Galili, U.** Glucocorticoid-induced lysis of human leukemia cells. In: Prediction of Response to Cancer Therapy, Ed. T.C. Hall, Alan R. Liss Scientific Publications, p. 43-59, 1988.
2. **Galili, U., E. Kobrin, B.A. Macher and S.B. Shohet.** Anti-Gal and red cell aging. Prog. Clin. Biol. Res. The Red Cell: 7th Ann Arbor Conference, A.L. Liss Publisher, 225-245, 1989.
3. **Galili, U.** Alpha-galactosyl (anti-Gal) autoantibodies. In: Autoantibodies, Eds. Y. Shoenfeld and J.B. Peter, Elsevier 1996, pp. 24-30.

4. **Galili, U.** The α -galactosyl epitope (Gal α 1-3Gal β 1-4GlcNAc-R) and the natural anti-Gal antibody. In: *Molecular Biology and Evolution of Blood Groups and MHC Antigens in Primates*, Eds. W.W. Socha and A. Blancher, Springer Verlag 1997, pp. 236-253.
5. **Galili, U.** Anti-Gal damage beyond hyperacute rejection. In: *Xenotransplantation*, Eds. D.C. Kooper, E. Kemp, J.L. Platt and D.J.G. White, Springer Verlag, Hiedelberg 1997, pp. 95-103.
6. **Galili, U.** Evolution of α -galactosyltransferase. In: " α -Gal and Anti-Gal : α 1,3galactosyltransferase, α -gal epitopes and the natural anti-Gal antibody." Eds. Galili, U. and J.L. Avila. Plenum Press, "Subcellular Biochemistry", Vol. **32**:1-24, 1999.
7. **Galili, U.,** L. Wang and M.Z. Radic. The natural anti-Gal antibody. In: " α -Gal and Anti-Gal : α 1,3galactosyltransferase, α -gal epitopes and the natural anti-Gal antibody." Eds. Galili, U. and J.L. Avila. Plenum Press, "Subcellular Biochemistry", Vol. **32**:79-104, 1999.
8. Rother, R. and **U. Galili.** α -Gal epitopes on viral glycoproteins. In: " α -Gal and Anti-Gal : α 1,3galactosyltransferase, α -gal epitopes and the natural anti-Gal antibody." Eds. Galili, U. and J.L. Avila. Plenum Press, "Subcellular Biochemistry", Vol. **32**:143-172, 1999.
9. Henion, T.R. and **U. Galili.** Structure-function studies on the α 1,3galactosyltransferase gene. In: " α -Gal and Anti-Gal : α 1,3galactosyltransferase, α -gal epitopes and the natural anti-Gal antibody." Eds. Galili, U. and J.L. Avila. Plenum Press, "Subcellular Biochemistry", Vol. **32**:49-78, 1999.
10. LaTemple, D.C. and **U. Galili.** Enhancement of tumor vaccine immunogenicity by anti-Gal. In: " α -Gal and Anti-Gal : α 1,3galactosyltransferase, α -gal epitopes and the natural anti-Gal antibody." Eds. Galili, U. and J.L. Avila. Plenum Press, "Subcellular Biochemistry", Vol. **32**:361-380, 1999.
11. **Galili, U.** Anti-Gal and autoimmunity: Role of anti-Gal in Graves' disease pathogenesis. In: " α -Gal and Anti-Gal : α 1,3galactosyltransferase, α -gal epitopes and the natural anti-Gal antibody." Eds. Galili, U. and J.L. Avila. Plenum Press, "Subcellular Biochemistry", Vol. **32**:311-360, 1999.
12. **Galili, U.** Natural xenoreactive antibodies. In: *Xenotransplantation- Basic Research and Clinical Application*. J.L. Platt Editor, Humana Press, Totowa NJ, 2002.
13. **Galili, U.** The interaction between anti-Gal and the α -gal epitope as an immunologic barrier to xenotransplantation. In: *Immunology of Carbohydrates*, edited by SYC. Wong and G. Arsequell, Kluwer Academic/Plenum Publishers, 2003.
14. **Galili, U.** Evolution and clinical significance of the α -gal epitope (Gal α 1-3Gal β 1-4GlcNAc-R). In: *Comprehensive Glycoscience*, Elsevier, Editor in Chief- J.P. Kamerling, Volume **3**, pp. 225-235, 2007.
15. **Galili, U.** Anti-Gal and anti-non gal barriers in xenotransplantation. In *XENOTRANSPLANTATION 2011 Book*, S. Miyagawa Editor.
16. **Galili, U.** Human Anti-Gal and Anti-non Gal Immune Response to Porcine Tissue Implants. In: "Host Response to Biomaterials", Badylak S.F. Editor, Elsevier publisher, pp. 239-262, 2015.
17. Stone K.R., **Galili, U.** Xenograft Ligaments. In: Nakamura N., Zaffagnini S., Marx R., Musahl V. (eds) *Controversies in the Technical Aspects of ACL Reconstruction*. Springer, Berlin, Heidelberg, . 2017.

18. **Galili, U.** “Glycoengineering of vaccines that harness the natural anti-Gal antibody increases immune protection in viral epidemics” in the book “Epidemics: Detecting, Predicting and Preventing” Nova publisher, 2021.

Invited Reviews and Manuscripts

1. Schlesinger, M. and **U. Galili**. The effect of neuraminidase on the formation of E-rosettes by human peripheral lymphocytes and sheep red blood cells. *Behring Inst. Mitt* **55**:272-276, 1974.
2. Klein, E., F. Vanky, **U. Galili**, B. Vose and M. Fope. In situ expression of tumor immunity. *Contem. Top. Immunobiol.* **10**:79-107, 1980.
3. **Galili, U.** and A. Polliack. The human prothymocyte and its leukemic counterpart. Proc. Leuk. Markers, Ed. W. Knapp, Academic Press, 1981, pp. 149-152, 1981.
4. Galili, N. and **U. Galili**. Glucocorticoid-induced lysis of various subsets of acute lymphoblastic leukemia. *Hematol. Blood Transfusion* **28**:146-148, 1983.
5. **Galili, U.** Prothymocytes. *Immunol. Hematol. Res. Monograph No.* **2**:303-314, 1984.
6. **Galili, U.**, I. Flechner and E.A. Rachmilewitz. A naturally occurring anti- α -galactosyl IgG recognizing senescent human red cells. In: Cellular and Molecular Aspects of Aging, Ed. J. Eaton, Alan R. Liss Scientific Publications, 263-276, 1985.
7. Rachmilewitz, E.A., E. Shinar, O. Shalev, **U. Galili** and S.L. Schrier. Erythrocyte membrane alterations in β -thalassemia. *Clin Haematol.* **14**:163-182, 1985.
8. **Galili, U.**, M.R. Clark and S.B. Shoheit. Excessive binding of the natural anti- α -galactosyl IgG to sickle red cells: Enhancement of red cell destruction by a physiological process. *Trans. Assoc. Am. Physicians Vol* XCVIII, 158-165, 1985.
9. **Galili, U.** The natural anti-Gal antibody, the B-like antigen, and human red cell aging. *Blood Cells* **14**:205-220, 1988.
10. **Galili, U.** The two antibody specificities within human anti-blood group B antibodies. *Transfusion Med. Rev.* **2**:112-121, 1988.
11. **Galili, U.** and B.A. Macher. Interaction between anti-Gal and human tumor cells: A natural defense mechanisms? An Editorial. *J. Natl. Cancer Inst.* **81**:178-179, 1989.
12. **Galili, U.**, A. Thall and B.A. Macher. Evolution of the Gal α 1-3 Gal β 1-4 GlcNAc-R epitope in mammals. *Trends in Glycoscience and Glycotechnology*, **2**:303-318, 1990.
13. **Galili, U.** The human natural anti-Gal antibody and infectious agents. *Infect. Immun. (Life Sci. Adv.)* **10**:41-46, 1991.
14. **Galili, U.** The natural anti-Gal antibody: Evolution and autoimmunity in man. *Immunol Ser.* **55**:355-73, 1991.

15. **Galili, U.** Evolution and pathophysiology of the human natural anti-Gal antibody. *Springer Seminars in Immunopathology* **15**:155-171, 1993.
16. **Galili, U.** Significance of the natural human anti-Gal antibody in xenotransplantation. *Xeno* **2**:84-87, 1994.
17. **Galili, U.,** A. Tibell, B. Samuelsson, L. Rydberg and C.G. Groth. Anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. *Xenotransplantation* **2**:188-192, 1995.
18. **Galili, U.,** C.R. Gregory and R.E. Morris. New World monkeys as a primate model for xenografts in the absence of anti-Gal. *Transplant. Proc.* **28**:572-573, 1996.
19. **Galili, U.,** A. Tibell, B. Samuelsson, L. Rydberg and C.G. Groth. Increased anti-Gal activity in diabetic patients transplanted with porcine islet cells. *Transplant. Proc.* **28**:569-571, 1996.
20. **Galili, U.,** O. Minanov, R.E. Michler and K.R. Stone. High affinity anti-Gal IgG in chronic rejection of xenografts. *Xenotransplantation*, **4**:127-131, 1997.
21. **Galili, U.** Significance of anti-Gal IgG in chronic xenograft rejection. *Transplant. Proc.* **31**:940-941, 1999.
22. **Galili, U.** Anti-Gal antibody prevents xenotransplantation. *SCIENCE & MEDICINE* Sept./Oct. 1998, pp. 32-41.
23. Gregory, C.R., **Galili, U.,** Hancock, W.W., Valverde, C.R., Griffey, S.M., Berryman, E.R. and Morris, R.E.. Squirrel monkeys hyperacutely reject porcine musculocutaneous flaps despite a lack of naturally occurring xenoantibodies. *Transplant. Proc.* **30**:1082-1083, 1998.
24. Tanemura, M., and **U. Galili** T cells interacting with the α -gal epitope: Studies in α 1,3galactosyltransferase knock out mice. *Transplant. Proc.* **32**: 921-923, 2000.
25. Tanemura, M., and **U. Galili** Differential expression of the α -gal epitope on pig and mouse organs. *Transplant. Proc.* **32**: 843, 2000.
26. Tanemura, M., D., Yin, A. S. Chong and **U. Galili.** Differential immune response to carbohydrate epitopes on allo- and xenografts: Implications for accommodation. *Transplant. Proc.* **32**: 991-993, 2000.
27. Chen, Z.C., and **U. Galili** Genes coding for anti-Gal in knock-out mice for the α 1,3galactosyltransferase gene: analysis by hybridomas and by combinatorial phage display libraries. *Transplant. Proc.* **32**: 846-847, 2000.
28. Tanemura, M., and **U. Galili** Identification of B cells with receptors for α -gal epitopes (Gal α 1-3Gal β 1-4GlcNAc-R) in xenograft recipients. *Transplant. Proc.* **32**: 857-858, 2000.
29. **Galili, U.** and M. Tanemura Significance of α -gal (Gal α 1-3Gal β 1-4GlcNAc-R) epitopes and α 1,3galactosyltransferase in xenotransplantation. *Trends in Glycoscience and Glycotechnology (TIGG)* **11**: 317-327, 2000.
30. **Galili, U.,** Z.C. Chen, M. Tanemura, T. Seregina and C.J. Link. Understanding the induced antibody response (in xenograft recipients). *GRAFT* **4**:32-35, 2001.

31. **Galili, U.**, Preformed and elicited antibodies to pig antigens in nonhuman primates and humans. *Curr. Opin. Organ Transplant.* **6**: 30-35, 2001.
32. **Galili, U.** The nature of elicited xenoantibodies. *Transplant. Proc.* **33**: 688-689, 2001.
33. **Galili, U.**, Z-C Chen, O. Manches, J. Plumas and H. Preisler, Preparation of autologous leukemia and lymphoma vaccines expressing α gal epitopes. *Journal of Hemotherapy & Stem Cell Research* **10**: 501-511, 2001.
34. **Galili, U.** The α -gal epitope (Gal α 1-3Gal β 1-4GlcNAc-R) in xenotransplantation. *Biochimie* **83**: 557-563, 2001.
35. **Galili, U.** The α -gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. *Immunology and Cell Biology* **83**: 674-686, 2005.
36. **Galili, U.** Xenotransplantation and ABO incompatible transplantation: The similarities they share. *Transfusion and Apheresis Science*, **35**: 45-58, 2006.
37. Macher, B. A, and **U. Galili**. The Gal α 1,3Gal β 1,4GlcNAc-R (α -Gal) epitope: a carbohydrate of unique evolution and clinical relevance. *Biochem. Biophys. Acta.* **1780**: 75-88, 2008.
38. **Galili, U.**, A. Albertini, P. Sondel, K. Wigglesworth, M. Sullivan and G. Whalen. In situ conversion of melanoma lesions into autologous vaccine by intratumoral injections of α -gal glycolipids. *CANCERS* **2**: 773-793, 2010.
39. **Galili, U.** Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of α -Gal Glycolipids That Induce Anti-Gal/ α -Gal Epitope Interaction. *Clin. Develop. Immunology*, 2011: 2011.
40. **Galili, U.** In situ conversion of tumors into autologous tumor associated antigen vaccines by intratumoral injection of α -gal glycolipids. *Oncoimmunology* **2**: 1-3, 2013.
41. **Galili, U.** Discovery of the natural anti-Gal antibody and its past and future relevance to medicine. *Xenotransplantation* **20**: 138–147, 2013.
42. **Galili, U.** Increasing the immunogenicity of HIV and influenza virus vaccines by anti-Gal mediated targeting to antigen presenting cells. *Current Topics in Virology*, **12**: 1-12, 2014.
43. **Galili, U.** Inhalation of α -gal/sialic acid liposomes: a novel approach for inhibition of influenza virus infection. *Future Virol.* **11**: 95 -99, 2016.

CLINICAL TRIAL ACTIVITIES

Researcher initiated clinical trials with INDs approved by the FDA (submitted by Uri Galili)

1. IND-9685: “Autologous tumor cell membranes enzymatically treated to express α -galactosyl epitopes” (Approval date 04/19/2002).
2. IND-11183: “ α -Gal modified autologous neoplastic lymphohematologic vaccine” (Approval date 10/22/2003).

3. IND-12946: “Glycosphingolipids expressing α -gal epitopes; Administered intratumoral” (Approval date 01/18/2007).

RESEARCH GRANTS AND CONTRACTS

Leukemia Society of America	Glucocorticoid effects on leukemia cells
Principal Investigator:	U. Galili
Years of Award:	1984-1985
Total Direct Costs/Yr:	\$70,000
NIH DK-32094	Red cell membrane.
Principal Investigator:	Steven B. Shohet
Years of Award:	1986 - 1991
American Cancer Society	α 1-3 galactosyltransferase in human normal and malignant cells.
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$100,000
Years of Award:	1989 - 1991
NIA NIH R01AG-06299	Anti-Gal on human red cells: A model for cell aging.
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$180,000
Years of Award:	1986 - 1994
NIH R01 GM-40205 (subcontract)	Gal α 1-3Gal glycoconjugates: Biochemical and evolutionary aspects.
Principal Investigator:	B.A.Macher
Total Direct Costs/Yr:	\$70,000
Years of Award:	1987 - 1995
Mizutani Foundation for Glycoscience	Reactive sites and regulation of primate α -1,3galactosyltransferase
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$60,000
Years of Award:	1993 - 1995
NIH R01 Subcontract	H-2, α -galactosyl epitopes and tumors
Principal Investigator:	E. Gorelik
Total Direct Costs/Yr:	\$30,519
Years of Award:	1994 - 1997
NIH R01 AG/AI1307	Molecular changes in antibody affinity in the elderly
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$157,000
Years of Award:	1996 - 1999
NIH SBIR (subcontract)	Pig articular cartilage as xenograft in monkeys
Principal Investigator:	Kevin R. Stone, M.D.
Total Direct Costs/Yr:	\$32,000

Date of Award:	April 1998
NIH R01 CA85868	Enhancing tumor vaccine immunogenicity by anti-Gal
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$142,000
Years of Award:	1999-2002
NIH SBIR (subcontract)	Pig articular cartilage as xenograft in monkeys
Cross Cart, Inc.	\$52,000/year
Principal Investigator:	U. Galili
Years of Award:	1999-2001
NIH R01 AI45849	Preventing anti-Gal production by α -gal toxin
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$175,000/year
Years of Award:	2000-2003
American Heart Association	Preventing anti-Gal activity by anti-Gal scFv
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$50,000
Years of Award:	2002-2004
NIH R21 AI58749	Increase gp120 immunogenicity/linked to α -gal epitopes
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$150,000/year
Years of Award:	Sept. 2004- August 2006
NIH R01CA122019	Xenograft-like rejection of tumors by α -gal glycolipids
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$210,000 (pre-cut \$250,000)
Years of Award:	Feb. 2008- Jan. 2011
UMass Development grant	Acceleration of wound healing by α -gal nanoparticles
	U. Galili
	\$25,000
	2010-2011
UMass Development grant	Regeneration of post ischemia myocardium by α -gal nanoparticles
	U. Galili
	\$25,000
	2012-2013
NIH R21 CA130295	Intratatumoral injection of α -gal glycolipids in stage IV melanoma: Phase I trial
Principal Investigator:	U. Galili
Total Direct Costs/Yr:	\$221,000/year (pre-cut \$250,000)
Years of Award:	Feb. 2009- Jan. 2012
Baum Foundation	Post-MI myocardium regeneration by α -gal nanoparticles

PATENTS (Uri Galili):

1. Compositions and methods for vaccines comprising α -galactosyl epitopes
Patent number: 5879675, Issued: March 9, 1999.
2. Anterior cruciate ligament xenografts, (with KR Stone) Patent number: 6210440, Issued: April 3, 2001
3. Compositions and methods for vaccines comprising α -galactosyl epitopes, Patent number: 6361775,
Issued: March 26, 2002.
4. Methods and compositions for preventing anti-Gal production in xenograft recipients, (with KR Stone)
Patent number: 6613330, Issued: September 2, 2003.
5. Soft tissue xenografts, (with KR Stone) Patent number: 6758865, Issued: July 6, 2004.
6. Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that
result in anti-Gal antibody binding, Patent number: 7820628, Issued: October 26, 2010.
7. Compositions and methods for wound healing, Patent number: 8084057, Issued: December 27, 2011.
8. Compositions and methods for wound healing, Patent number: 8440198, Issued: May 14, 2013.
9. Compositions and methods for wound healing, Patent number: 8865178, Issued: October 21, 2014.
10. Glycolipid containing compositions for use in the treatment of tumors, Patent number: 10092586,
Issued: October 9, 2018.
11. Compositions and methods for increasing immunogenicity of glycoprotein vaccines, Patent
number: 9662383, Issued: May 30, 2017.
12. Compositions and methods for increasing immunogenicity of glycoprotein vaccines, Patent
number: 10201601, Issued: February 12, 2019.

REVIEWING MANUSCRIPTS FOR:

Proceedings of the National Academy of Science of USA
Blood
Biomaterials
Journal of Immunology
Immunology Today
Glycoconjugate Journal
Experimental Gerontology
Journal of Clinical Investigation
Journal of Biological Chemistry
Natural Immunity
Nature Medicine
Transplantation
Xenotransplantation

EDITORIAL BOARD:

Archives in Biophysics and Biochemistry

REVIEWING GRANTS FOR:

International Association for Cancer Research
Wellcomb Research Foundation

Australian National Health and Medical Research Council
Luxemburg Science Foundation
NIH-NCI “Cancer Immunotherapy” Study Section